Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients

Abstract Background Quality of life (QoL) data for patients with inflammatory bowel disease switched from the reference infliximab to biosimilar CT-P13 is lacking. This study aims to demonstrate noninferiority for QoL and efficacy after switching. Methods OoL and clinical efficacy were measured prior to and after 2, 4, and 6 CT-P13 infusions. Results One hundred seventy-eight patients were included. Noninferiority was established for QoL [ratio 97.95% (95% confidence interval 95.93 to 100.01)] and efficacy [difference −0.02 (95% confidence interval −0.68 to 0.64)]. Five patients reported 6 nonrelated, serious adverse events. Conclusions Switching from reference infliximab to CT-P13 did not affect the QoL or disease activity and was well tolerated.

[1]  P. Declerck,et al.  Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology? , 2020, Rheumatology and Therapy.

[2]  A. Amiot,et al.  Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[3]  T. Molnár,et al.  Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective , 2019, Therapeutic advances in gastroenterology.

[4]  G. Bakalos,et al.  Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review. , 2019, Clinical therapeutics.

[5]  B. Feagan,et al.  Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab , 2018, Alimentary pharmacology & therapeutics.

[6]  O. Grip,et al.  Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease , 2018, Therapeutic advances in gastroenterology.

[7]  Gregory A. Heindel,et al.  The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies , 2018, Journal of managed care & specialty pharmacy.

[8]  G. D'Haens,et al.  Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. , 2018, The lancet. Gastroenterology & hepatology.

[9]  A. Boonen,et al.  Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial , 2017, The Lancet.

[10]  Inge Christoffer Olsen,et al.  Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial , 2017, The Lancet.

[11]  W. El-Matary.  Patient-reported outcome measures in inflammatory bowel disease. , 2014, Canadian journal of gastroenterology & hepatology.

[12]  A. Ford,et al.  Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. , 2012, Journal of Crohn's & colitis.

[13]  D. Jewell,et al.  Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. , 2011, Journal of Crohn's & colitis.

[14]  K. Van Steen,et al.  Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  W. Koldingsnes,et al.  The economic burden of TNFα inhibitors and other biologic treatments in Norway , 2011, ClinicoEconomics and outcomes research : CEOR.

[16]  Stefan Schreiber,et al.  Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[18]  P. Rutgeerts,et al.  Review article: infliximab therapy for inflammatory bowel disease – seven years on , 2006, Alimentary pharmacology & therapeutics.

[19]  M. Schwartz,et al.  Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis , 2005, Gut.

[20]  I. Vermes,et al.  [Calprotectin: a fecal marker for diagnosis and follow-up in patients with chronic inflammatory bowel disease]. , 2003, Nederlands tijdschrift voor geneeskunde.

[21]  M. Welfare,et al.  Defining Relapse of Ulcerative Colitis Using a Symptom-based Activity Index , 2003, Scandinavian journal of gastroenterology.

[22]  Huub Schellekens,et al.  Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.

[23]  L. Påhlman,et al.  Health-Related Quality of Life and Psychological Distress in a Population-based Sample of Swedish Patients with Inflammatory Bowel Disease , 2002, Scandinavian journal of gastroenterology.

[24]  R. Pounder,et al.  A simple clinical colitis activity index , 1998, Gut.

[25]  J. Bartelsman,et al.  Inflammatory Bowel Disease Questionnaire: cross-cultural adaptation and further validation , 1995, European journal of gastroenterology & hepatology.

[26]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[27]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON CONDUCT OF PHARMACOVIGILANCE FOR MEDICINES USED BY THE PAEDIATRIC POPULATION , 2007 .